Group 1 - Monteverde & Associates PC is investigating Pieris Pharmaceuticals, Inc. regarding its proposed merger with Palvella Therapeutics, Inc. [1] - Under the merger agreement, Pieris shareholders are expected to own approximately 18% of the combined company [1] - Monteverde & Associates PC has been recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report [1] Group 2 - The firm has a successful track record in recovering money for shareholders and litigating class actions [2] - Monteverde & Associates PC operates from the Empire State Building in New York City [2] - The firm emphasizes the importance of legal representation and encourages potential clients to inquire about their experience and success rates [2]

Core Viewpoint - Ademi LLP is investigating Pieris for potential breaches of fiduciary duty and other legal violations related to its merger transaction with Palvella [1][3]. Transaction Details - Pieris will issue shares of common stock to pre-merger Palvella stockholders in exchange for the cancellation of Palvella's capital stock, resulting in Palvella becoming a wholly-owned subsidiary of Pieris [2]. - Post-merger, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company, while pre-merger Palvella stockholders are expected to own approximately 82%, subject to adjustments and additional shares from a concurrent private placement [2]. - Pieris pre-merger stockholders will receive a contingent value right (CVR) for potential payments from proceeds under existing partnership agreements with Pfizer and Boston Pharmaceuticals [2]. Investigation Focus - The investigation is centered on the conduct of Pieris' board of directors and their fulfillment of fiduciary duties to all shareholders [3]. - Concerns have been raised regarding the transaction agreement, which allegedly imposes significant penalties on Pieris for accepting competing bids, potentially limiting shareholder value [5]. - Pieris insiders are expected to receive substantial benefits as part of the change of control arrangements [5].

Pieris Pharmaceuticals (NASDAQ:PIRS) stock is rocketing higher on Wednesday after announcing a merger agreement with Palvella Therapeutics. Pieris Pharmaceuticals and Palvella Therapeutics will enact an all-stock transfer for this merger. That will result in Pieris Pharmaceuticals issuing shares of PIRS stock to Palvella stockholders. This will cancel out those investors shares of capital stock of Palvella. Pieris Pharmaceuticals notes that after the merger, 18% of the combined company will belong to pre-me ...

Avacta Group plc London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. "Avacta is at a pivotal ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 ( ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission file number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada EIN 30-0784346 (State or other jurisdiction of incorporation or organization) FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37471 30-0784346 (State or other jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Registrant's telephone number, including area code: 857-246-89 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-07843 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Nevada 30-0784346 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 ( ...